Wensu Wei

565 total citations
33 papers, 312 citations indexed

About

Wensu Wei is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Wensu Wei has authored 33 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Pulmonary and Respiratory Medicine and 12 papers in Oncology. Recurrent topics in Wensu Wei's work include Renal cell carcinoma treatment (10 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Wensu Wei is often cited by papers focused on Renal cell carcinoma treatment (10 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Wensu Wei collaborates with scholars based in China, France and United States. Wensu Wei's co-authors include Fangjian Zhou, Minhua Deng, Rixin Chen, Zhuowei Liu, Xiangdong Li, Ning Wang, Dan Xie, Yunlin Ye, Yulu Peng and Lijuan Jiang and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and American Journal Of Pathology.

In The Last Decade

Wensu Wei

27 papers receiving 309 citations

Peers

Wensu Wei

PRM

SURGE

ONCOL

Fujiang Xu China

Kanghua Xiao China

Maoyu Wang China

Yugang Ge China

Dongwei Xue China

Yunping Zhao China

Chutian Xiao China

Maithili P. Dalvi United States

Zhicheng Yu China

Fujiang Xu China

Wensu Wei

180 ×0.7

92 ×0.9

96 ×1.3

PRM

27 ×0.6

SURGE

49 ×1.1

ONCOL

Citations per year, relative to Wensu Wei Wensu Wei (= 1×) peers Fujiang Xu

Countries citing papers authored by Wensu Wei

Since Specialization

Citations

This map shows the geographic impact of Wensu Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wensu Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wensu Wei more than expected).

Fields of papers citing papers by Wensu Wei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wensu Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wensu Wei. The network helps show where Wensu Wei may publish in the future.

Co-authorship network of co-authors of Wensu Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Wensu Wei. A scholar is included among the top collaborators of Wensu Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wensu Wei. Wensu Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tan, Xiangyu, Kai Yao, Zhiming Wu, et al.. (2025). 3079P Efficacy and safety results from Formula-01: A phrase II study of Disitamab Vedotin plus BCG in HER2 high expression high-risk non-muscle invasive bladder cancer patients (HR-NMIBC). Annals of Oncology. 36. S1490–S1491.

Wang, Yanjun, Yiqi Yu, Rongyuan Zheng, et al.. (2025). Neutrophil-to-lymphocyte ratio predicts a poor prognosis for penile cancer with an immunosuppressive tumor microenvironment. Frontiers in Immunology. 16. 1568825–1568825.

Huang, Tingxuan, Yulu Peng, Wensu Wei, et al.. (2025). Clinical effectiveness and safety of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): a single-center retrospective study. World Journal of Urology. 43(1). 99–99. 1 indexed citations

Wang, Xiaotong, Tao Huang, Huan‐Yao Lei, et al.. (2025). Immediate and sustained effects of acupuncture on the default mode network. Brazilian Journal of Psychiatry. 47. e20254202–e20254202.

Wei, Wensu, Lijuan Jiang, Zhi-Ling Zhang, et al.. (2024). Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.. Journal of Clinical Oncology. 42(16_suppl). 4544–4544. 1 indexed citations

Tang, Yi, et al.. (2024). The role of TROP-2 in the progression and target therapy in penile squamous cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). e17023–e17023. 1 indexed citations

Huang, Tingxuan, Yulu Peng, Ruiqi Liu, et al.. (2024). Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy. International Immunopharmacology. 142(Pt B). 113106–113106. 3 indexed citations

Chen, Yifei, Haifeng Huang, Zhongxiong Lai, et al.. (2024). Phylogenetic Relationships Plays a More Important Role than Environmental Factors in Influencing Leaf Si and Ca Stoichiometry Along the Elevation Gradient in a Chinese Subtropical Forest. Forests. 15(12). 2154–2154.

Deng, Minhua, Zhaohui Zhou, Jiawei Chen, et al.. (2024). Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer. Advanced Science. 12(5). e2408599–e2408599. 5 indexed citations

10.

Huang, Tingxuan, Jun Wang, Ruiqi Liu, et al.. (2023). Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study. Clinical Genitourinary Cancer. 22(2). 252–260.e3. 2 indexed citations

11.

Wang, Ning, Rixin Chen, Minhua Deng, et al.. (2023). m5C-dependent cross-regulation between nuclear reader ALYREF and writer NSUN2 promotes urothelial bladder cancer malignancy through facilitating RABL6/TK1 mRNAs splicing and stabilization. Cell Death and Disease. 14(2). 139–139. 64 indexed citations

12.

Dong, Pei, Wensu Wei, Lijuan Jiang, et al.. (2023). Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma: Preliminary results from an exploratory prospective clinical study.. Journal of Clinical Oncology. 41(16_suppl). e16546–e16546.

13.

Peng, Yulu, Jun Wang, Zhen Li, et al.. (2022). Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis. Cancer Medicine. 11(19). 3674–3686. 3 indexed citations

14.

Dong, Pei, Yulu Peng, Ruiqi Liu, et al.. (2022). Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clinical Cancer Research. 28(21). 4807–4819. 12 indexed citations

15.

Liu, Yang, Zhiling Zhang, Ruiqi Liu, et al.. (2021). Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma. Radiation Oncology. 16(1). 211–211. 12 indexed citations

16.

Chen, Xin, Zhuowei Liu, Wensu Wei, et al.. (2021). Correction to: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway. Journal of Experimental & Clinical Cancer Research. 40(1).

17.

Wei, Wensu, Ning Wang, Minhua Deng, et al.. (2021). LRPPRC regulates redox homeostasis via the circANKHD1/FOXM1 axis to enhance bladder urothelial carcinoma tumorigenesis. Redox Biology. 48. 102201–102201. 33 indexed citations

18.

Li, Xiangdong, Pei Dong, Wensu Wei, et al.. (2019). Overexpression of CEP72 Promotes Bladder Urothelial Carcinoma Cell Aggressiveness via Epigenetic CREB-Mediated Induction of SERPINE1. American Journal Of Pathology. 189(6). 1284–1297. 13 indexed citations

19.

Chen, Xin, Zhuowei Liu, Wensu Wei, et al.. (2018). Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway. Journal of Experimental & Clinical Cancer Research. 37(1). 115–115. 16 indexed citations

20.

Wei, Jingchao, et al.. (2016). Rapid progression of mixed neuroendocrine carcinoma-acinar adenocarcinoma of the prostate: A case report. Oncology Letters. 12(2). 1019–1022. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact